{"id":27323,"date":"2024-06-21T09:45:00","date_gmt":"2024-06-21T09:45:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4445309_AE45309_0"},"modified":"2024-06-21T09:45:00","modified_gmt":"2024-06-21T09:45:00","slug":"biocytogen-awarded-u-s-patent-for-renlite-common-light-chain-mouse-platform","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=27323","title":{"rendered":"Biocytogen Awarded U.S. Patent for RenLite\u00ae Common Light Chain Mouse Platform"},"content":{"rendered":"\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">BEIJING<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">June 21, 2024<\/span><\/span> \/PRNewswire\/ &#8212; Biocytogen Pharmaceuticals (<span class=\"xn-location\">Beijing<\/span>) Co., Ltd. (&quot;Biocytogen&quot;, HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite<sup>&reg; <\/sup>fully human common light chain mouse platform.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder4034\">\n<p style=\"TEXT-ALIGN: center; WIDTH: 100%\"><a href=\"https:\/\/mma.prnasia.com\/media2\/2444526\/RenLite______________EN.html\" target=\"_blank\" rel=\"nofollow noopener\"><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2444526\/RenLite______________EN.jpg?p=medium600\" title=\"\" alt=\"\" \/><\/a><br \/><span><\/span><\/p>\n<\/p><\/div>\n<p>RenLite mice, developed using Biocytogen&#8217;s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE<sup>TM<\/sup>) technology,&nbsp;feature the <i>in situ<\/i> replacement of the entire human antibody heavy chain variable region genes and a single light chain variable region gene. This enables the generation of highly diverse fully human antibodies that share a common light chain, effectively avoiding light-heavy chain mismatches during the assembly of bispecific antibodies, thereby significantly reducing the complexity of the CMC process. The molecular structures of these bispecific antibodies resemble monoclonal antibodies, exhibiting favorable physicochemical properties. Leveraging RenLite and RenLite KO mice, Biocytogen has generated a library of antibodies targeting over 200 TAA targets, enabling the rapid development of bispecific antibody and bispecific antibody-drug-conjugate (ADC) therapies.<\/p>\n<p>In addition to the RenLite platform, Biocytogen&#8217;s independently developed RenMice<sup>&reg;<\/sup>&nbsp;series includes RenMab<sup>TM<\/sup>, RenNano<sup>&reg;<\/sup>, RenTCR<sup>TM<\/sup> and RenTCR-mimic<sup>TM<\/sup> platforms. These five fully human antibody\/TCR mouse platforms cater to the diverse R&amp;D needs of pharmaceutical companies globally. Since their debut in 2019, the RenMice platforms have garnered widespread recognition within the biotech and pharmaceutical industries. As of <span class=\"xn-chron\">December 31, 2023<\/span>, Biocytogen has established 47 target-nominated RenMice licensing projects with over 20 multinational corporations (MNCs) and biopharmaceutical\/biotech companies, including Merck KGaA, Janssen, Xencor, BeiGene and Innovent. The RenMice platform has generated a library of over 400,000 fully human antibodies against thousands of targets and high-quality candidate antibodies, facilitating 103 projects encompassing co-development, out-licensing, and transfer agreements.<\/p>\n<p>The U.S. patent authorization for the RenLite platform technology demonstrates Biocytogen&#8217;s exceptional innovation capabilities and global competitiveness.&nbsp;Biocytogen will continue to pursue&nbsp;global patent strategies and protect key technologies, offering advanced technology platforms and robust intellectual property protection for its partners. Besides <span class=\"xn-location\">the United States<\/span>, patent applications for the RenLite platform have been submitted in <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">Europe<\/span>, <span class=\"xn-location\">Japan<\/span>, <span class=\"xn-location\">South Korea<\/span>, <span class=\"xn-location\">Canada<\/span>, <span class=\"xn-location\">Singapore<\/span>, <span class=\"xn-location\">Russia<\/span>, <span class=\"xn-location\">Israel<\/span>, <span class=\"xn-location\">Australia<\/span>, and other countries and regions with authorizations in progress.<\/p>\n<p><b>About Biocytogen <\/b><\/p>\n<p>Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice<sup>&reg;<\/sup> (RenMab<sup>TM<\/sup>\/RenLite<sup>&reg;<\/sup>\/RenNano<sup>&reg;<\/sup>\/RenTCR-mimic<sup>TM<\/sup>) platforms for fully human monoclonal\/bispecific\/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics<sup>TM<\/sup>, to explore global partnerships for an off-the-shelf library of &gt;400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of <span class=\"xn-chron\">December 31, 2023<\/span>, 103 therapeutic antibody and multiple clinical asset co-development\/out-licensing\/transfer agreements and 47 target-nominated RenMice<sup>&reg;<\/sup> licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company&#8217;s sub-brand, BioMice<sup>TM<\/sup>, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in <span class=\"xn-location\">Beijing<\/span>, Biocytogen has branches in <span class=\"xn-location\">China<\/span> (Haimen Jiangsu, <span class=\"xn-location\">Shanghai<\/span>), <span class=\"xn-location\">USA<\/span> (<span class=\"xn-location\">Boston<\/span>, <span class=\"xn-location\">San Francisco<\/span>), and <span class=\"xn-location\">Germany<\/span> (Heidelberg). For more information, please visit <a href=\"http:\/\/en.biocytogen.com.cn\/\" target=\"_blank\" rel=\"nofollow noopener\">http:\/\/en.biocytogen.com.cn<\/a>.<\/p>\n<p><b>Biocytogen Contacts<\/b><\/p>\n<p>Antibody assets and platforms: <a href=\"mailto:BD-Licensing@biocytogen.com\" target=\"_blank\" rel=\"nofollow noopener\">BD-Licensing@biocytogen.com<\/a><br \/>Press Contact: <a href=\"mailto:pr@bbctg.com.cn\" target=\"_blank\" rel=\"nofollow noopener\">pr@bbctg.com.cn<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEIJING, June 21, 2024 \/PRNewswire\/ &#8212; Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (&quot;Biocytogen&quot;, HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite&reg; fully human common light chain mouse platform. RenLite mice, developed using Biocytogen&#8217;s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCETM) technology,&nbsp;feature the in situ replacement of the entire [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-27323","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biocytogen Awarded U.S. Patent for RenLite\u00ae Common Light Chain Mouse Platform - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=27323\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen Awarded U.S. Patent for RenLite\u00ae Common Light Chain Mouse Platform - My Blog\" \/>\n<meta property=\"og:description\" content=\"BEIJING, June 21, 2024 \/PRNewswire\/ &#8212; Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (&quot;Biocytogen&quot;, HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite&reg; fully human common light chain mouse platform. RenLite mice, developed using Biocytogen&#8217;s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCETM) technology,&nbsp;feature the in situ replacement of the entire [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=27323\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-21T09:45:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/2444526\/RenLite______________EN.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=27323#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=27323\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Biocytogen Awarded U.S. Patent for RenLite\u00ae Common Light Chain Mouse Platform\",\"datePublished\":\"2024-06-21T09:45:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=27323\"},\"wordCount\":553,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=27323#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2444526\\\/RenLite______________EN.jpg?p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=27323\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=27323\",\"name\":\"Biocytogen Awarded U.S. Patent for RenLite\u00ae Common Light Chain Mouse Platform - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=27323#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=27323#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2444526\\\/RenLite______________EN.jpg?p=medium600\",\"datePublished\":\"2024-06-21T09:45:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=27323#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=27323\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=27323#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2444526\\\/RenLite______________EN.jpg?p=medium600\",\"contentUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2444526\\\/RenLite______________EN.jpg?p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=27323#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen Awarded U.S. Patent for RenLite\u00ae Common Light Chain Mouse Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biocytogen Awarded U.S. Patent for RenLite\u00ae Common Light Chain Mouse Platform - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=27323","og_locale":"en_US","og_type":"article","og_title":"Biocytogen Awarded U.S. Patent for RenLite\u00ae Common Light Chain Mouse Platform - My Blog","og_description":"BEIJING, June 21, 2024 \/PRNewswire\/ &#8212; Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (&quot;Biocytogen&quot;, HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite&reg; fully human common light chain mouse platform. RenLite mice, developed using Biocytogen&#8217;s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCETM) technology,&nbsp;feature the in situ replacement of the entire [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=27323","og_site_name":"My Blog","article_published_time":"2024-06-21T09:45:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/2444526\/RenLite______________EN.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=27323#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=27323"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Biocytogen Awarded U.S. Patent for RenLite\u00ae Common Light Chain Mouse Platform","datePublished":"2024-06-21T09:45:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=27323"},"wordCount":553,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=27323#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/2444526\/RenLite______________EN.jpg?p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=27323","url":"https:\/\/transmediavictoria.net.au\/?p=27323","name":"Biocytogen Awarded U.S. Patent for RenLite\u00ae Common Light Chain Mouse Platform - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=27323#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=27323#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/2444526\/RenLite______________EN.jpg?p=medium600","datePublished":"2024-06-21T09:45:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=27323#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=27323"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=27323#primaryimage","url":"https:\/\/mma.prnasia.com\/media2\/2444526\/RenLite______________EN.jpg?p=medium600","contentUrl":"https:\/\/mma.prnasia.com\/media2\/2444526\/RenLite______________EN.jpg?p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=27323#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Biocytogen Awarded U.S. Patent for RenLite\u00ae Common Light Chain Mouse Platform"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/27323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=27323"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/27323\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=27323"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=27323"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=27323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}